Functional consequences of mTOR inhibition

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 1, 2010, Pages 31-40

  Sudarsanam, Sucha ^a   Johnson, Dale E ^a  

^a Emiliem Inc   (United States)

Author keywords

Cancer; Diabetes; Lifespan extension; MTOR; Ocular disease; Rapamycin; Sirolimus

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CURCUMIN; EM 101; EVEROLIMUS; IMATINIB; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NVPBEZ 235; PALOMID 529; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 765;

ACNE; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; EYE DISEASE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY CARCINOMA; LIFE EXTENSION; MACULOPAPULAR RASH; MOUTH PAIN; MUCOSA INFLAMMATION; NONHUMAN; ONCOLOGY; PNEUMONIA; PROSTATE CANCER; REVIEW; STOMATITIS; UVEITIS;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EYE DISEASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; LONGEVITY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 73849137944     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Vézina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (1975) 28(10):721-726.
2. Lempiäinen H, Halazonetis TD: Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J (2009) 28(20): 3067-3073.
3. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer (2009) 9(8):550-562.
4. Obici S: Minireview: Molecular targets for obesity therapy in the brain. Endocrinology (2009) 150(6):2512-2517.
5. Ni Z, Hui P: Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica (2009) 223(6):401-410.
6. Pei JJ, Hugon J: mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med (2008) 12(6B):2525-2532.
7. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ: Reversal of learning deficits in a TSC2+/- mouse model of tuberous sclerosis. Nat Med (2008) 14(8): 843-848.
8. Liang J, Choi J, Clardy J: Refined structure of the FKBP12- rapamycin-FRB ternary complex at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr (1999) 55(Pt 4):736-744.
9. Zeng Z, Sarbassov DD, Samudio IJ, Yee KW, Munsell MF, Jackson CE, Giles FJ, Sabatini DM, Andreeff M, Konopleva M: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2007) 109(8):3509-3512.
10. Yang Q, Guan KL: Expanding mTOR signaling. Cell Res (2007) 17(6):666-681.
11. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 17(6):596-603.
12. Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell (2007) 12(4):487-502.
13. Keniry M, Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene (2008) 27(41): 5477-5485.
14. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 284(12):8023-8032.
15. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM: Active-site inhibitors of mTOR target rapamycinresistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 7(2):e38.
16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the RICTOR-mTOR complex. Science (2005) 307(5712):1098-1101.
17. Dong J, Pan D: TSC2 is not a critical target of Akt during normal Drosophila development. Genes Dev (2004) 18(20):2479-2484.
18. Schleich S, Teleman AA: Akt phosphorylates both TSC1 and TSC2 in Drosophila, but neither phosphorylation is required for normal animal growth. PLoS ONE (2009) 4(7):e6305.
19. García-Martínez JM, Alessi DR: mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 416(3):375-385.
20. Zhang J, Gao Z, Yin J, Quon MJ, Ye J: S6K directly phosphorylates IRS-1 on Ser270 to promote insulin resistance in response to TNF-α signaling through IKK2. J Biol Chem (2008) 283(51):35375-35382.
21. Grant S: Cotargeting survival signaling pathways in cancer. J Clin Invest (2008) 118(9):3003-3006.
22. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 121(2):179-193.
23. Meijer AJ, Dubbelhuis PF: Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun (2004) 313(2):397-403.
24. Rini BI: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res (2008) 14(5):1286-1290.
25. Atkins MB, Yasothan U, Kirkpatrick P: Everolimus. Nat Rev Drug Discov (2009) 8(7):535-536.
26. Molckovsky A, Siu LL: First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. J Hematol Oncol (2008) 1:20.
27. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P: Targeting the PI3K-Akt-mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 8(4):393-412.
28. Guertin DA, Sabatini DM: The pharmacology of mTOR inhibition. Sci Signal (2009) 2(67):pe24.
29. Kok K, Geering B, Vanhaesebroeck B: Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci (2009) 34(3):115-127.
30. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA (2005) 102(3):802-807.
31. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA (1999) 96(8):4240-4245.
32. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N et al: A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 39(4):503-512.
33. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell (2007) 12(1):9-22.
34. Sinclair DA: Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev (2005) 126(9):987-1002.
35. Partridge L, Gems D: Mechanisms of ageing: Public or private? Nat Rev Genet (2002) 3(3):165-175.
36. Guarente L, Kenyon C: Genetic pathways that regulate ageing in model organisms. Nature (2000) 408(6809):255-262.
37. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Müller F: Genetics: Influence of TOR kinase on lifespan in C elegans. Nature (2003) 426(6967):620.
38. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S: Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol (2004) 14(10):885-890.
39. Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S: Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev (2006) 20(2):174-184.
40. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R: Caloric restriction delays disease onset and mortality in rhesus monkeys. Science (2009) 325(5937): 201-204.
41. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M et al: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 460(7253):392-395.
42. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L et al: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5(1):e8.
43. Congdon NG, Friedman DS, Lietman T: Important causes of visual impairment in the world today. JAMA (2003) 290(15): 2057-2060.
44. Leiderman YI, Miller JW: Proliferative vitreoretinopathy: Pathobiology and therapeutic targets. Semin Ophthalmol (2009) 24(2):62-69.
45. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J: Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis (2004) 10:964-972.
46. Boehm S, Rothermundt C, Hess D, Joerger M: Antiangiogenic drugs in oncology: A focus on drug safety and the elderly - A minireview. Gerontology (2009): doi:10.1159/000262450.
47. Zhou P, Zhao MW, Li XX, Yu WZ, Bian ZM: siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy. Curr Eye Res (2007) 32(11):973-984.
48. Stahl A, Paschek L, Martin G, et al: Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett (2008) 582(20):3097-3102.
49. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM, Dua HS: The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol (2005) 89(6):666-669.
50. Boura-Halfon S, Zick Y: Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab (2009) 296(4):E581-E591.
51. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 431(7005):200-205.
52. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyó JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol (2006) 17(5):1395-1404.
53. Wang C, Kim H, Hiroi Y, Sawada N, Salomone S, Benjamin LE, Walsh K, Moskowitz MA, Liao JK: Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 2(62):ra11.
54. La Cava A, Matarese G: The weight of leptin in immunity. Nat Rev Immunol (2004) 4(5):371-379.
55. Maya-Monteiro CM, Almeida PE, D'Avila H, Martins AS, Rezende AP, Castro-Faria-Neto H, Bozza PT: Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent mechanism. J Biol Chem (2008) 283(4):2203-2210.
56. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ: Hypothalamic mTOR signaling regulates food intake. Science (2006) 312(5775):927-930.
57. Hartford CM, Ratain MJ: Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 82(4):381-388.
58. Sessa C, Tosi D, Viganò L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N et al: Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol (2009): doi:10.1093/annonc/mdp504.
59. Sankhala K, Mita A, Kelly K, Mahalingham D, Giles F, Mita M: The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol (2009) 4(2):135-142.
60. Kurmasheva RT, Huang S, Houghton PJ: Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 95(8): 955-960.
61. Jiang BH, Liu LZ: Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat (2008) 11(3):63-76.
62. Liu T, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevria C, Yung WK: NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 8(8):2204-2210.
63. Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J: LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther (2005) 314(3):1134-1143.
64. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE: Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res (2008) 68(22):9551-9557.
65. Alvero AB, Montagna MK, Chen R, Kim KH, Lyungjin K, Visintin I, Fu HH, Brown D, Mor G: NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer (2009) 115(14):3204-3216.
66. Beevers CS, Chen L, Liu L, Webster NJ, Huang S: Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res (2009) 69(3):1000-1008.
67. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 14(14):4491-4499.
68. Sarkar FH, Li Y: Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev (2009):doi:10.1016/j.ctrv. 2009.07.001.
69. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest (2008) 118(9):3065-3074.
70. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 118(9):3051-3064.
71. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG: Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA (2004) 101(9):3130-3135.
72. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA: Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 4(11):691-699.
73. Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer- Bruneel MF, Peraldi MN, Kreis H: Characteristics of sirolimusassociated interstitial pneumonitis in renal transplant patients. Transplantation (2001) 72(5):787-790.
74. Pham PT, Pham PT, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH: Sirolimus-associated pulmonary toxicity. Transplantation (2004) 77